Compare TSLX & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | VCEL |
|---|---|---|
| Founded | 2010 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2011 | 1996 |
| Metric | TSLX | VCEL |
|---|---|---|
| Price | $18.32 | $33.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $22.13 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 1.6M | 423.1K |
| Earning Date | 05-14-2026 | 05-18-2026 |
| Dividend Yield | ★ 11.18% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 1.81 | 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.09 |
| Revenue Next Year | $1.92 | $17.96 |
| P/E Ratio | ★ $10.13 | $105.00 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $16.99 | $29.24 |
| 52 Week High | $25.17 | $49.10 |
| Indicator | TSLX | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 37.46 |
| Support Level | N/A | $29.59 |
| Resistance Level | $22.46 | $38.48 |
| Average True Range (ATR) | 0.62 | 1.57 |
| MACD | 0.08 | -0.34 |
| Stochastic Oscillator | 55.28 | 10.53 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.